Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sceptical US FDA panel gives nod for Astellas overactive bladder drug

This article was originally published in Scrip

Executive Summary

With a somewhat tone of scepticism, a panel of advisers to the US FDA on 5 April backed approval of Astellas Pharma's experimental overactive bladder (OAB) drug mirabegron, voting 7-4, with one abstention, that the investigational medicine's benefits outweighed its risks of elevated heart rate, blood pressure and liver toxicity.

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC016886

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel